Americas was Teleflex’s largest segment in fiscal 2025, bringing in $1.28B of $1.99B (64%).
| Segment | FY 2009 | FY 2012 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Americas | $1.93B | $1.18B | $1.28B | ||||||||||
| Critical Care | — | — | — | ||||||||||
| Emea | $558.37M | $316.97M | $472.41M | ||||||||||
| Vascular North America | — | — | — | ||||||||||
| Asia | $306.32M | $214.76M | $241.11M | ||||||||||
| Surgical Care | — | — | — | ||||||||||
| All Other | — | — | — | ||||||||||
| Anesthesia North America | — | — | — | ||||||||||
| Oem | — | — | — | ||||||||||
| Anesthesia Respiratory North America | — | — | — | ||||||||||
| Surgical North America | — | — | — | ||||||||||
| Oem & Development Services | — | — | — | ||||||||||
| Interventional North America | — | — | — | ||||||||||
| Cardiac Care | — | — | — | ||||||||||
| Other | — | — | — | ||||||||||
| Total | $2.79B | $1.71B | $1.99B |
Teleflex brought in $1.99B from its three segments in fiscal 2025, the year ended December 31, 2025. That was up 16.4% from $1.71B in fiscal 2023, the previous year with figures. Americas was the largest at $1.28B (64.2%), ahead of Emea at $472.41M (23.7%) and Asia at $241.11M (12.1%).
Compared with fiscal 2023, the previous year with figures, Emea grew fastest, up 49.0% to $472.41M. Every segment above 2% of revenue grew. From fiscal 2022 to 2025, combined revenue from these segments fell from $2.79B to $1.99B, a compound annual decline of 10.6%. Americas' share of the total fell from 69.0% to 64.2%.
United States was Teleflex’s largest region in fiscal 2025, bringing in $1.18B of $1.99B (59%).
| Geography | FY 2009 | FY 2010 | FY 2011 | FY 2012 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $1.79B | $1.11B | $1.18B | ||||||||||||
| U.S | — | — | — | ||||||||||||
| Europe | $622.34M | $330.07M | $484.73M | ||||||||||||
| Asia & Asia Pacific | — | — | — | ||||||||||||
| Emea | — | — | — | ||||||||||||
| Other Europe | — | — | — | ||||||||||||
| Other Americas | — | — | — | ||||||||||||
| Asia Pacific | $270.75M | $187.95M | $218.03M | ||||||||||||
| Asia | — | — | — | ||||||||||||
| Spain, Italy, Portugal, & Greece | — | — | — | ||||||||||||
| Germany | — | — | — | ||||||||||||
| Oem | — | — | — | ||||||||||||
| All Other | $111.48M | $87.53M | $108.13M | ||||||||||||
| Total | $2.79B | $1.71B | $1.99B |
Teleflex brought in $1.99B from its four regions in fiscal 2025, the year ended December 31, 2025. That was up 16.4% from $1.71B in fiscal 2023, the previous year with figures. United States was the largest at $1.18B (59.3%), ahead of Europe at $484.73M (24.3%) and Asia Pacific at $218.03M (10.9%). The remaining region, All Other, brought in $108.13M.
Compared with fiscal 2023, the previous year with figures, Europe grew fastest, up 46.9% to $484.73M. Every region above 2% of revenue grew. From fiscal 2022 to 2025, combined revenue from these regions fell from $2.79B to $1.99B, a compound annual decline of 10.6%. United States' share of the total fell from 64.0% to 59.3%.
Vascular Access was Teleflex’s largest product and service line in fiscal 2025, bringing in $917.73M of $1.99B (46%).
| Product and Service | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2025 |
|---|---|---|---|---|---|---|---|---|
| Vascular Access | $683.61M | $841.11M | $917.73M | |||||
| Interventional | $445.02M | $407.25M | $647.79M | |||||
| Surgical | $392.92M | $388.33M | $418.16M | |||||
| Anesthesia | $388.89M | — | — | |||||
| Other | $285.15M | $75.75M | $9.04M | |||||
| Interventional Urology | $322.83M | — | — | |||||
| Oem | $272.62M | — | — | |||||
| Total | $2.79B | $1.71B | $1.99B |
Teleflex brought in $1.99B from its four product and service lines in fiscal 2025, the year ended December 31, 2025. That was up 16.4% from $1.71B in fiscal 2023, the previous year with figures. Vascular Access was the largest at $917.73M (46.1%), ahead of Interventional at $647.79M (32.5%) and Surgical at $418.16M (21.0%). The remaining line, Other, brought in $9.04M.
Compared with fiscal 2023, the previous year with figures, Interventional grew fastest, up 59.1% to $647.79M. Every line above 2% of revenue grew.
Teleflex stopped reporting Anesthesia ($388.89M in fiscal 2022), Interventional Urology ($322.83M in fiscal 2022) and Oem ($272.62M in fiscal 2022) as separate lines.
Teleflex (TFX) reports its revenue by segment, by geography and by product and service. In fiscal 2025, Americas was its largest segment, bringing in $1.28B (64.2% of the total), followed by Emea at $472.41M (23.7%).
Americas was Teleflex's largest segment in fiscal 2025, bringing in $1.28B, or 64.2% of the $1.99B total across its three segments.
United States was Teleflex's largest region in fiscal 2025, bringing in $1.18B, or 59.3% of the $1.99B total across its four regions.
Vascular Access was Teleflex's largest product and service line in fiscal 2025, bringing in $917.73M, or 46.1% of the $1.99B total across its four product and service lines.
Every figure comes from Teleflex's annual financial filings, as reported. Each line keeps the name Teleflex gives it, and years follow its fiscal calendar.
Teleflex's revenue by segment goes back to fiscal 2009, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.